In preclinical studies, the combined administration of recombinant human interleukin (rhIL)-7-hyFc (efineptakin alfa; NT-I7), hIL-2/TCB2 complex (SLC-3010), and PD-1 inhibitor robustly promoted the expansion of Tpex cells in TDLNs of a melanoma model and facilitated their differentiation into a highly cytotoxic effector subpopulation, achieving complete tumor regression[221]. Here, PDCD1 is linked to melanoma.